Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Patenting DNA.

Martin Bobrow1, Sandy Thomas

  • 1Department of Medical Genetics, Cambridge Institute for Medical Research, Wellcome/MRC Building, Addenbrooke's Hospital, Cambridge, CB2 2XY, UK.

Current Opinion in Molecular Therapeutics
|February 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Victor McKusick and his role in the founding of the European School of Genetic Medicine.

American journal of medical genetics. Part A·2021
Same author

Consent recommendations for research and international data sharing involving persons with dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2018
Same author

A new global research agenda for food.

Nature·2016
Same author

Food systems: Nourish as well as feed the world.

Nature·2016
Same author

RESEARCH ETHICS. Ethics review for international data-intensive research.

Science (New York, N.Y.)·2016
Same author

A decision tool to guide the ethics review of a challenging breed of emerging genomic projects.

European journal of human genetics : EJHG·2016
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Patenting human DNA sequences is debated. While useful for creating medicines, patenting discoveries and research tools requires higher inventiveness thresholds for DNA sequences.

Area of Science:

  • Biotechnology Law
  • Intellectual Property Rights
  • Molecular Biology

Background:

  • The patent system is the primary mechanism for protecting inventions involving human DNA sequences.
  • Significant debate exists regarding the ethical and legal acceptability of patenting DNA sequences.
  • Universities and companies have filed numerous patent applications for DNA sequences over the last decade.

Purpose of the Study:

  • To analyze the justification for patenting human DNA sequences.
  • To examine the challenges in meeting inventiveness criteria for DNA sequence patents.
  • To differentiate between patenting discoveries versus inventions in the context of DNA.

Main Methods:

  • Legal analysis of patent law principles applied to DNA sequences.

Related Experiment Videos

  • Examination of inventiveness criteria in relation to advancing DNA isolation technology.
  • Evaluation of arguments for and against patenting DNA sequences as research tools and chemical intermediates.

    • Main Results:

    • Patenting DNA sequences as research tools is rarely justified due to difficulties in meeting inventiveness criteria.
    • Patenting DNA sequences as chemical intermediates for therapeutic protein production is considered reasonable.
    • The discovery of gene-disease associations is argued to be a discovery, not an invention.

    Conclusions:

    • Raising patentability thresholds for DNA sequences could address current legal and technical complexities.
    • Current patent law allows discoveries to be claimed if useful, but inventiveness for DNA is increasingly difficult to justify.
    • While patenting DNA for therapeutic manufacturing is reasonable, broader patenting of DNA discoveries warrants stricter criteria.